Compassionate Use of a 5-HT3-Receptor Antagonist, Tropisetron, in Patients Refractory to Standard Antiemetic Treatment

This publication has 9 references indexed in Scilit:

• Methodology in anti-emetic trials.
  1991
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• The effect of three dose levels of ICS 205–930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1989
• Activity of a new antiemetic agent: alizapride
  Cancer Chemotherapy and Pharmacology, 1988
• FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS
  The Lancet, 1987
• Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
  Journal of Clinical Oncology, 1987
• CONSECUTIVE DOSE-FINDING TRIALS ADDING LORAZEPAM TO THE COMBINATION OF METOCLOPRAMIDE PLUS DEXAMETHASONE - IMPROVED SUBJECTIVE EFFECTIVENESS OVER THE COMBINATION OF DIPHENHYDRAMINE PLUS METOCLOPRAMIDE PLUS DEXAMETHASONE
  1985
• High-dose dexamethasone for prevention of cis-platin-induced vomiting
  Cancer Chemotherapy and Pharmacology, 1981
• Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting
  New England Journal of Medicine, 1981